Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enzyvant Sciences Ltd.

Division of Roivant Sciences Inc.
www.enzyvant.com

Latest From Enzyvant Sciences Ltd.

Will 'Vant' Deal Really Fulfill Dainippon's Needs?

Sumitomo Dainippon's planned $3bn deal with Roivant goes some way to fulfilling the Japanese firm's strategic needs, but investors appear cool and questions remain.

Business Strategies Deals

$3bn Roivant Deal To Fill Holes At Dainippon

Facing looming expiries for its top product, Japan’s Sumitomo Dainippon is planning to acquire multiple "vant" companies and their portfolios of clinical stage assets from Roivant, in a move to address mid-term challenges to revenues and following recent late-stage development failures.

M & A Business Strategies

After The Peak Of 2018’s US FDA Approval Record, 2019 Looks Like A Valley

FDA’s second half 2019 user fee calendar features almost 30 novel agents, but another record-breaking tally is out of reach.

Approvals Drug Approval Standards

Keeping Track: US FDA Closes Out First Half Of 2019 With CRL For Edsivo, But A Burst Of Supplemental Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.

Approvals Drug Review
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Roivant Sciences Inc.
  • Senior Management
  • Rachelle Jacques, CEO
    George O Elston, Head, Corp. Dev. & CFO
    Alan Kimura, MD, PhD, CMO
    Morgan Molloy, Chief Commercial Officer
    Judy Chuk, PhD, VP, Strategy & Operations
    Alex Tracy, PhD, VP, Pharmaceutical Dev. & Mnfctng.
  • Contact Info
  • Enzyvant Sciences Ltd.
    324 Blackwell St.
    Durham, NC 27701
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register